CDH2 and breast carcinoma: Results showed that the epithelial markers (ZO-1, E-Cadherin, ß-Catenin) were increased and mesenchymal markers (N-Cadherin, Vimentin, a-SMA) were downregulated after DHX9 knockdown in liver cancer, lung cancer and breast cancer cells, indicating that DHX9 promoted EMT in these cancers, however, the opposite results were detected in renal cell carcinoma cells (Figure 8G).